Results

Total Results: 2,080 records

Showing results for "drug".

201. Methods-Guidance-Reporting-Bias Methods (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-reporting-bias_methods.pdf
     November 01, 2013 - Food and Drug Administration. … Drug Approval Process Manufacturers are required to submit a New Drug Application to the FDA for all … The Drugs@FDA site may be searched by the generic or trade drug name (not drug class) for Statistical … Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication … Drug Effectiveness Review Project.

202. S149 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s149.pdf
     October 01, 2007 - that uses subclassification on a longitudinal pro- pensity score to compare outcomes between a new drug … We explored the usefulness of these methods in our study of a new drug for treatment of type 2 diabetes … The median date for first filling a pre- scription for this drug was mid-October 2005. … Because the drug was only recently approved, we had limited follow-up time. … Additionally, when studying a new drug, it is even less clear what are the predictors of use of the drug

203. rheumatoid-arthritis-medicine-update-protocol-170515 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine-update_research-protocol.pdf
     May 15, 2017 - Published online: May 15, 2017 Evidence-based Practice Center Systematic Review Protocol Project Title: Drug … However, data on disease-modifying antirheumatic drug (DMARD) use in the first 3 months are limited. … Food and Drug Administration; RA = rheumatoid arthritis; TNF = tumor necrosis factor; ts = targeted … Choosing a RA treatment drug can be difficult with these populations. … Drug Therapy for Rheumatoid Arthritis in Adults: An Update [Internet].

204. Horizon Scanning_Rapid Cost Analyses of Selected Potential High-Impact Intervention Reports (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/horizon-scan_research-2015.pdf
     January 01, 2015 - Food and Drug Administration (FDA) status of products subject to FDA regulation at the time the cost … health benefit a drug provides for a specific indication. … Whether these initiatives will alter drug pricing is unclear at this time, although Dr. … million to $180 million per year in costs of this new drug for the labeled indication. … Food and Drug Administration (FDA).

205. Management of Primary Headache During Pregnancy | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/headaches-pregnancy/protocol
     November 12, 2019 - Other drug within class. … Same drug(s), different route, treatment duration, initiation time, or other aspect. … Other drug within class. … Same drug(s), different route, treatment duration, initiation time, or other aspect. … Curr Drug Metab. 2012 May 1;13(4):474-90. PMID: 22299823. 15. U.S. Food and Drug Administration.

206. Treatment of Atrial Fibrillation | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/atrial-fibrillation/research
     June 28, 2013 - Drug enhancement of external electrical cardioversion demonstrated a benefit compared with no drug enhancement

207. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/juvenile-arthritis-dmards
     March 09, 2010 - Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Timeline January 01, 2005 Topic Initiated March 09, 2010 Research Protocol Archived The Effectiveness of Disease-Modifying Antirheumatic Drugs (DMARDS) in Chil…

208. Use of Antiplatelet Therapy in Patients Receiving Coronary Stents | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/coronary-stents-antiplatelet-therapy/abstract
     January 31, 2011 - Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: … Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting

209. Data Points #7: Utilization of anticancer biologic products among Medicare beneficiaries, by diagnostic cancer subchapter, 2006-2009 | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/cancer-drugs-utilization/research
     August 26, 2011 - Not all biologics are Food and Drug Administration-labeled (i.e., indicated) for the conditions in which … developed guidelines for medically accepted off-label use of anticancer biologics, using published drug … to integrate information from five various compendia providers (American Hospital Formulary Service Drug

210. EHC Protocol: Addressing Social Isolation To Improve Health of Older Adults: A Rapid Evidence Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-risk-drugs-protocol.pdf
     July 27, 2023 - Protocol Project Title: Making Healthcare Safer IV: Protocols for High-Risk Drugs: Reducing Adverse Drug … The “Protocols for High-Risk Drugs: Reducing Adverse Drug Events Related to Anticoagulants” as a patient … Event Prevention (ADE Action Plan) identified anticoagulants as a leading cause of adverse drug … cause-specific mortality, bleeding, hemorrhage, stroke, quality of life, adverse events associated with drug-drug … US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014.

211. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - (aspirin) versus VKA (2 RCTs, one NRCS), LMWH versus antiplatelet drug (2 NRCSs), antiplatelet drug … versus FXaI (1 RCT), antiplatelet drug versus mechanical devices (1 RCT, 1 NRCS), antiplatelet drug … drug and mechanical device; LMWH alone versus combinations of LMWH and antiplatelet drug, DTI, FXaI … drug, UFH, and mechanical device. … Across this study set, 12 classes were evaluated (antiplatelet drug [aspirin], antiplatelet drug plus

212. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - (aspirin) versus VKA (2 RCTs, one NRCS), LMWH versus antiplatelet drug (2 NRCSs), antiplatelet drug … versus FXaI (1 RCT), antiplatelet drug versus mechanical devices (1 RCT, 1 NRCS), antiplatelet drug … drug and mechanical device; LMWH alone versus combinations of LMWH and antiplatelet drug, DTI, FXaI … drug, UFH, and mechanical device. … Across this study set, 12 classes were evaluated (antiplatelet drug [aspirin], antiplatelet drug plus

213. #05 DEPRESSION (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1306.pdf
     October 01, 2014 - Mifepristone, a drug for psychotic major depression (PMD), a condition for which no U.S. … administration and is known to be a street drug of abuse. … Research suggests new drug targets for depression. … Food and Drug Administration (FDA) [accessed 2012 Mar 15]. [2 p]. … Washington (DC): Drug Enforcement Administration, U.S.

214. Making Healthcare Safer IV: Summary of Findings, 2023-2024 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/mhs-IV-1-year-final-report-updated-title_0.pdf
     May 01, 2024 - Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events ........ … Reducing Adverse Drug Events Related to Anticoagulant Use in Adults 9a. … involving CDSS to reduce medication errors and adverse drug events. … Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events 1a. … Reducing Adverse Drug Events Related to Anticoagulant Use in Adults 9a.

215. Antidepressant Treatment of Depression During Pregnancy and the Postpartum Period (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/depression-pregnancy-postpartum_executive.pdf
     July 01, 2014 - A vs. drug B)? … Using a second drug to augment the effects of the primary drug and comparing this treatment with monotherapy … with a single drug ii. … A vs. drug B)? … Using a second drug to augment the effects of the primary drug and comparing this treatment with monotherapy

216. Systematic Review of Calcineurin Inhibitors for Kidney Transplant | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/calcineurin-inhibitor/research-protocol
     October 14, 2014 - These patients present special challenges as there are drug-drug interactions between CNIs and protease … Studies that only evaluate drug pharmacokinetics will also be excluded. … Ther Drug Monit. 2009;31:139-52. Bouamar R, Shuker N, Hesselink DA, et al. … Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after … monitoring terms 'drug monitoring'/exp OR 'drug monitoring' OR ((drug OR therapy OR therapeutic) AND

217. Slide 1
     effectivehealthcare.ahrq.gov/sites/default/files/comparator-selection-in-observational-chapter-5.pptx
     January 01, 2013 - Pharmacoepidemiol Drug Saf 2006 May;15(5):291-303. … receiving drug B (comparison), as exposure to A is largely independent of exposure to B. … Pharmacoepidemiol Drug Saf 2006 May;15(5):291-303. … Paradoxical relations of drug treatment with mortality in older persons. … Dose/Intensity of Drug Comparison It is important to appreciate the effects of dose on outcomes.

218. Treatment of Depression During Pregnancy and the Postpartum Period | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/depression-pregnancy-postpartum/research-protocol
     March 29, 2013 - that are compared with drug only interventions. … A vs. drug B)? … The combinations include: Using a second drug to augment the effects of the primary drug and comparing … A vs. drug B)? … The combination include: (a) Using a second drug to augment the effects of the primary drug and comparing

219. depression-pregnancy-postpartum-protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/depression-pregnancy-postpartum_research-protocol.pdf
     March 29, 2013 - A vs. drug B)? … Using a second drug to augment the effects of the primary drug and comparing this treatment with monotherapy … with a single drug ii. … A vs. drug B)? … The combination include: (a) Using a second drug to augment the effects of the primary drug and

220. Acute Treatment for Episodic Migraine: Surveillance Report 2 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/episodic-migraine-surveillance-report-2.pdf
     June 01, 2022 - Reviews, PsycINFO®, and Scopus from September 2, 2021 to December 30, 2021.We also searched Food and Drug … Placebo From the previous report, NSAIDs as a drug class, compared with placebo, resolved pain at … No change in SOE supporting the effect of NSAIDs as a drug class vs. … analyses Abbreviations: KQ = Key Question; mg = milligram; NSAID = nonsteroidal anti-inflammatory drug … Therapy] 24 exp Vomiting/dt [Drug Therapy] 25 (((drug* or agent* or medication*) adj3 (nausea or